Outsourcing continues to increase in popularity within biopharma section, as a way to contain operational and infrastructure costs, as well as gain access to therapeutic and clinical trial expertise. Interactions between sponsors and CROs can sometimes be inefficient due to the large degree of shared responsibility. This paper examines the impact of centralized governance and optimized operating models on helping to realize the full potential of outsourcing arrangements. Download today.
White Paper September 11, 2013